Ostentus Therapeutics
Biotechnology startup developing plant-derived anticancer compounds. The company conducts preclinical pharmacology, analytical characterization, in vivo efficacy and preliminary toxicology studies to identify active molecules, define mechanisms of action, and support regulatory filings (pre-IND/IND) to enable first-in-human studies.
Industries
Nr. of Employees
small (1-50)
Ostentus Therapeutics
Newport Beach, California, United States, North America
Patents
Anti-oncogenic phytochemicals comprising substituted henicosanoic acid and henicosenoic acid
US-11918553-B2
View Details
Anti-oncogenic phytochemicals comprising substituted henicosanoic acid and henicosenoic acid
US-11918553-B2
View DetailsProducts
Plant-derived anticancer compound (OST-01, U.S. Pat. No. 11,918,553)
A multi-component plant-derived composition whose active constituents are being identified and characterized for anticancer activity in vitro and in vivo; supported by a U.S. patent.
OST-01
OST-01 is a plant-derived product with medicinal properties, composed of several structurally complex molecules that can be combined at different ratios to optimize therapeutic index, activity, and reduce toxicity. It has shown preliminary pharmacological activity and efficacy in vitro and in vivo in leukemia and cancer models.
Plant-derived anticancer compound (OST-01, U.S. Pat. No. 11,918,553)
A multi-component plant-derived composition whose active constituents are being identified and characterized for anticancer activity in vitro and in vivo; supported by a U.S. patent.
OST-01
OST-01 is a plant-derived product with medicinal properties, composed of several structurally complex molecules that can be combined at different ratios to optimize therapeutic index, activity, and reduce toxicity. It has shown preliminary pharmacological activity and efficacy in vitro and in vivo in leukemia and cancer models.
Services
Partnerships with cancer research institutions to fund and coordinate preclinical studies, analytical characterization, and efficacy testing.
Partnerships with cancer research institutions to fund and coordinate preclinical studies, analytical characterization, and efficacy testing.
Expertise Areas
- Natural product drug discovery
- Preclinical pharmacology
- Proteomics and metabolomics analysis
- In vivo efficacy testing (murine and PDX models)
Key Technologies
- Mass spectrometry (proteomics/metabolomics)
- Nuclear magnetic resonance (NMR) spectroscopy
- RNA sequencing (RNA-seq)
- Patient-derived xenograft models (PDX)
News & Updates
Press release announcing initiation of studies in collaboration with a cancer research institution to evaluate natural product compounds for leukemia and other cancers.
In vitro target validation in AML, colon, pancreas, prostate, breast and lung models completed.
Non-clinical efficacy studies in AML, colon, breast and lung xenograft models completed.
Preliminary toxicology in rodents, including organ assessments, completed.
Pre-IND filing discussions with the US FDA for OST-01 in AML completed to define path toward IND and Phase 1 studies.
Analytical identification and NMR analysis completed resulting in identification of multiple molecules (12 molecules reported).
Press release announcing initiation of studies in collaboration with a cancer research institution to evaluate natural product compounds for leukemia and other cancers.
In vitro target validation in AML, colon, pancreas, prostate, breast and lung models completed.
Non-clinical efficacy studies in AML, colon, breast and lung xenograft models completed.
Preliminary toxicology in rodents, including organ assessments, completed.
Pre-IND filing discussions with the US FDA for OST-01 in AML completed to define path toward IND and Phase 1 studies.
Analytical identification and NMR analysis completed resulting in identification of multiple molecules (12 molecules reported).